Rand A. Alattar
Hamad Medical Corporation(QA)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19, Antifungal resistance and susceptibility, COVID-19 and healthcare impacts
Most-Cited Works
- → Tocilizumab for the treatment of severe coronavirus disease 2019(2020)268 cited
- → The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study(2020)55 cited
- → Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report(2020)37 cited
- → Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs(2022)10 cited
- → The First Consecutive 5000 Patients with COVID-19 in Qatar; a Nation-wide Cohort Study(2020)9 cited
- → Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar(2021)2 cited
- → Coronavirus disease 2019 in solid organ transplant recipients in a setting of proactive screening and contact tracing(2021)1 cited
- → PAIN trial: phase II, single-center, double-blinded RCT comparing the efficacy of high dose of liposomal bupivacaine and standard bupivacaine periarticular injection in relieving immediate postoperative pain after total knee arthroplasty. Study protocol(2020)
- → Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study(2022)
- → 508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study(2021)